A PYMNTS Company

New Mexico Opens Suit Against Gilead, Bristol-Myers, Teva Over HIV Meds

By  |  February 25, 2021

Gilead Sciences, Bristol-Myers Squibb, Gilead Sciences, and Teva Pharmaceuticals were named in a lawsuit filed by New Mexico Attorney General Hector Balderas for violating the state’s Antitrust Act and Unfair Practices Act, reported Bloomberg.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The lawsuit, filed in the First Judicial District Court of New Mexico, stems from the development, marketing, and manufacturing of several antiretroviral medications used in the prevention and treatment of the HIV virus

    Lawsuit alleges that the defendants “engaged in coordinated schemes and anticompetitive agreements to suppress the entry of cheaper generic versions of each drug into the market, and to delay the development of safer drugs. 

    A press release from the attorney general explains that the lawsuit alleges that the defendants engaged in coordinated schemes and anti-competitive agreements in order to repress the entry of cheaper generic versions of each drug into the market and to hinder the development of safer, more effective treatment drugs as a means to maintain a grip on the market for antiretroviral treatment. The lawsuit claims these actions resulted in inflated prices for the lifesaving drugs as well as hundreds of millions of dollars in anticompetitive profits to the defendants.

    “Putting profits over the critical needs of New Mexican patients and risking their health and safety is unacceptable,” said Attorney General Balderas in a press release. “My office will hold anyone accountable who takes advantage of or harms our families.”

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.